Adults with type 1 diabetes who stopped taking semaglutide (Ozempic) saw a notable drop in blood sugar control within just three months, new extension study data shows. Time in range fell by 3.6 percentage points, while glucose variability worsened — even in patients using automated insulin delivery systems. Clinicians are urged to monitor patients closely during the transition off the drug.
Stopping Ozempic doesn't just mean losing its benefits — it can actively make blood sugar control worse. New data from the ADJUST-T1D extension study, presented at the Breakthrough T1D Clinical and Research Congress in Philadelphia, found that adults with type 1 diabetes who discontinued semaglutide experienced a significantly greater decline in glycemic control compared to those who had been on placebo all along.
The original ADJUST-T1D trial enrolled 72 adults with type 1 diabetes and obesity, all using automated insulin delivery systems. The extension study tracked 58 of those participants for three months after the trial ended, revealing that the benefits of semaglutide don't persist once the drug is stopped.
By the Numbers:
Why it matters: These findings send a clear message to clinicians: when patients with type 1 diabetes stop semaglutide, closer CGM monitoring, insulin setting reassessment, and timely follow-up are essential. The drug doesn't replace insulin — and its glycemic benefits don't linger after discontinuation.
